SYNTHESIS OF CONGENERS & PRODRUGS

同系物的合成

• 批准号: 6316173
• 负责人: DAVID C. BAKER
• 金额: --
• 依托单位: UNIVERSITY OF TENNESSEE KNOXVILLE
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6316173
• 关键词: alkaloids; drug design /synthesis /production; heterocyclic compounds; lead; nucleosides; peptides; prodrugs

The specific objectives of this project are to design and synthesize the following: 1. Congeners of lead compounds having confirmed activity, to enhance activity or potency. 2. Prodrugs with structural modifications that may provide improved pharmacokinetics, altered drug transport, improved bio-availability through increased water solubility, or increased chemical stability. 3. Other altered structures that possess elements of both congener and prodrug. Modifications of a lead may also include partial structures. 4. Compounds related to natural products, e.g., such as alkaloids, heterocycles, nucleosides, peptides.

这个项目的具体目标是设计和合成 以下是： 1.具有确认活性的先导化合物的同系物，以增强 活力或效力。 2.具有结构修饰的前药，可提供改进的 药代动力学，改变药物传输，提高生物利用度 通过增加水的溶解度，或增加化学稳定性。 3.其他同时具有同类元素和元素的改变的结构 前药。引线的修饰也可以包括部分结构。 4.与天然产品有关的化合物，例如生物碱、 杂环、核苷、多肽。

项目成果

A chiral rhodium complex for rapid asymmetric transfer hydrogenation of imines with high enantioselectivity.

• DOI: 10.1021/ol990098q
• 发表时间: 1999-08
• 期刊: Organic letters
• 影响因子: 5.2
• 作者: Jianmin Mao;David C. Baker